March 22, 2021
FPMAJ Director General Toshihiko Miyajima The Japanese government should change course on its de-facto price cutting measures for on-patent medicines towards the next reimbursement policy reform in April 2022, an executive of Japan’s umbrella pharma trade organization told Jiho on...read more